Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma

Molecular Medicine Reports

Volumn 10, Issue 2, 2014, Pages 737-742

  Zhu, Yalong ^a   Zhou, Jianhua ^a   Ji, Ying ^a   Yu, Baoqing ^a  

^a FUDAN UNIVERSITY PUDONG MEDICAL CENTER   (China)

Author keywords

AKT2; Event free survival; Immunohistochemistry; Osteosarcoma; Overall survival

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE B BETA; AKT2 PROTEIN, HUMAN; PROTEIN KINASE B;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE TISSUE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; BONE NEOPLASMS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REGRESSION ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84903307322     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2314     Document Type: Article

References (22)

1. Dorfman HD and Czerniak B: Bone cancers. Cancer 75 (Supp 1): 203-210, 1995.
2. Jaffe N: Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication. Cancer Treat Res 152: 219-37, 2009.
3. Kong C and Hansen MF: Biomarkers in osteosarcoma. Expert Opin Med Diagn 3: 13-23, 2009.
4. Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L and Evangelisti C: The emerging multiple roles of nuclear Akt. Biochim Biophys Acta 1823: 2168-2178, 2012.
5. Hemmings BA and Restuccia DF: PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 4: a011189, 2012.
6. Alessi DR and Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8: 55-62, 1998. (Pubitemid 28122141)
7. Radisavljevic Z: AKT as locus of cancer positive feedback loops and extreme robustness. J Cell Physiol 228: 522-524, 2013.
8. Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71: 829-842, 2013.
9. Lee MW, Kim DS, Lee JH, et al: Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci 102: 1822-1828, 2011.
10. Kirkegaard T, Witton CJ, Edwards J, et al: Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 56: 203-211, 2010
11. Xu X, Sakon M, Nagano H, et al: Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11: 25-32, 2004.
12. Zhang G, Li M, Zhu X, Bai Y and Yang C: Knockdown of akt sensitizes osteosarcoma cells to apoptosis induced by Cisplatin treatment. Int J Mol Sci 12: 2994-3005, 2011.
13. Chen D, Zhang YJ, Zhu KW and Wang WC: A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol 34: 1895-1899, 2013.
14. Busaidy NL, Farooki A, Dowlati A, et al: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30: 2919-2928, 2012.
15. Cheng JQ, Godwin AK, Bellacosa A, et al: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
16. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205, 2002. (Pubitemid 34213570)
17. Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA and Testa JR: Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14: 2793-2801, 1997. (Pubitemid 27313411)
18. Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17: 69-95, 2012.
19. Mahajan K and Mahajan NP: PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 227: 3178-3184, 2012.
20. Hafsi S, Pezzino FM, Candido S, et al: Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 40: 639-644, 2012
21. Toker A: Achieving specificity in Akt signaling in cancer. Adv Biol Regul 52: 78-87, 2012.
22. Shimura T: Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res 52: 539-544, 2011